A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J

Elpida Therapeutics SPC3 个研究点分布在 1 个国家目标入组 20 人2024年7月29日

概览

简要总结

This is a multicenter, longitudinal, prospective observational natural history study of subjects with a molecularly confirmed diagnosis of CMT4J. The study will enroll 20 subjects of any age into a uniform protocol for follow-up and evaluations. Subject visits will occur every 12 months + 4 weeks for up to 2 years.

详细描述

This is a multicenter, longitudinal, prospective observational natural history study of subjects with a molecularly confirmed diagnosis of CMT4J. The study will enroll 20 subjects of any age into a uniform protocol for follow-up and evaluations. The study will obtain demographic and medical history information. Natural history data will be collected prospectively on an annual basis and may include physical/neurological exams, standard laboratory tests, CMT outcome and disability measures, neuropsychological tests, nerve conduction studies (NCS), and imaging studies (muscle MRI). Pulmonary function test (PFT) and scoliosis series x-ray Subject visits will occur every 12 months + 4 weeks for up to 2 years. Subjects who terminate from the study prior to Visit 3 will undergo an early termination/end of study visit (EOS) if possible. The early termination/end of study visit is comprised of the Visit 3 assessments. If needed, the Investigator may conduct unscheduled visits with Sponsor's approval. No investigational product will be used during the study.

注册库

clinicaltrials.gov

开始日期

2024年7月29日

结束日期

2032年3月1日

最后更新

3个月前

研究类型

Observational

性别

All

研究者

发起方

Elpida Therapeutics SPC

责任方

Sponsor

入排标准

入选标准

•Male or female, all ages
•A molecularly-confirmed diagnosis of CMT4J (confirmed by a CLIA certified, CE-marked, or equivalent lab): Genomic DNA mutation analysis demonstrating 1) bi-allelic pathogenic and/or likely pathogenic variants (by ACMG criteria) in the FIG4 gene, or 2) bi-allelic variants with one pathogenic and/or likely pathogenic variant in trans with a variant of uncertain significance if laboratory evidence and expert consensus exits in support of loss of FIG4 function exists.
•Informed consent from patients 18 years or older who are able to provide consent and from caregivers; parent(s)/guardian(s) providing consent for subjects younger than 18 years at Screening and patients older than 18 years unable to provide informed consent
•Informed assent of patients younger than 18 years at Screening who are able to provide assent
•Able and willing to comply with the study protocol, including travel to Study Center, procedures, measurements and visits

排除标准

•Any known genetic abnormality, including chromosomal aberrations that confound the clinical phenotype
•Current participation in an interventional or therapeutic study
•Receiving an investigational drug within 90 days of the Baseline Visit
•Prior or current treatment with gene or stem cell therapy
•Any other diseases which may significantly interfere with the assessment of CMT4J
•Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the subject unsuitable for inclusion or could interfere with the subject participating in or completing the study